This study evaluated the inhibitory effects of 2,4,6-trihydroxy,3-nitro-benzamide (THNB) derivatives against hepatitis C virus (HCV). protease and other human serine proteases. The inhibitory efficacy was tested with a reversed-phase HPLC assay system using a NS3-NS4A fusion protein as the HCV protease and a synthetic peptide substrate that mimics the NS5A-5B junction. Twelve THNB derivatives showed more than 50% inhibition at 100 Jlg mL-1. The most potent derivative was RD3-4082, with 50% inhibition at a concentration of 2.3 Jlg mL-l; this concentration was lower than those of other protease inhibitors reported previously. The most selective derivative was RD2-4039, with 50% inhibition at a concentration of 32.8 Jlg mL-1, a lower concentration than those against other serine proteases (chymotrypsin, trypsin, plasmin and elastase). These results suggest that the RD2-4039 skeleton is an important structure for inhibitory activity against the HCV protease NS3-NS4A.
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Hepatitis C virus (HCV) is a positive-stranded RNA virus (Choo et al., 1989) and has been classified into its own genus within the family Flaviviridae (Wengler et al., 1991) . HCV contains a genome that encodes a single,long polyprotein with the gene order: S'-C-E1-E2-p7-NS2-NS3-NS4A-NS4B-NSSA-NSSB-3', where E are the envelopeproteins and NS are non-structural proteins. The HCVprotein NS3 displays serine protease-like enzymatic activity in the cleavage of the NS3-4A, NS4A-4B, NS4B-SA and NSSA-SB junctions (Bartenschlager et al, 1993; Eckart et al., 1993; Grakoui et al., 1993a,b; Hijikata et al., 1993; Tomei et al., 1993) . The HCV protein NS4A acts as an effector or cofactor in the protease .activity of NS3. Furthermore, Shimizu et al. (1996) used a synthetic peptide substrate that mimics the NSSA-SB junction to demonstrate that residues 22-31 of NS4A are required for its effector activity. The proteolytic processing steps in the HCV life cycle are most likely required to produce infectious virus particles; this makes viral proteases primary targets for antiviral agents.
Recently, we established an in vitro assay system for screening inhibitors of the NS3-NS4A protease, using reversed-phase HPLC and a synthetic peptide substrate that mimics the NSSA-SB junction . The inhibitory effects of serine protease inhibitors against this HCV protease have been reported. However, they were inhibitive only at high concentrations . To develop novel HCV protease inhibitors, we performed a random screening assayfor compounds in our chemical library using the established HPLC system. We found that 2,4,6-trihydroxy,3-nitro-benzamide (THNB) derivatives inhibited NS3-NS4A protease activity. Furthermore, we evaluated the inhibitory effects of these inhibitors against other serine proteases.
The 20-mer peptide Dansyl-GEAGDDIVPCSM-SYTWTGAL-OH, which mimics the NSSA-SB junction, was synthesized on an automated multiple peptide synthesizer (Model PSSM-8; Shimazu, Kyoto, Japan). The peptide was purified by preparative reversed-phase HPLC (ODS-80Tm, 2.1Sx30 cm; Tosoh, Tokyo, Japan). Its purity was 92.7%.
The region of the HCV genome encoding NS3-NS4A for expression in Escherichia coli was selected for the active enzyme. This genomic region spans nucleotides
3421-5475 (amino acids 1027-1711). We expressed the NS3-4A fusion protein as a complex with maltose-binding protein (MBP), which has an affinity for specific ligands that assist enzyme purification, as described previously .
HCV NS3-NS4A protease activity was determined in a total volume of200~L of assaybuffer (50 mM Tris-HCI pH 7.6 containing 30 mM NaCI, 1 mM CaCI 2 , and 2 mM DTT) containing 1.4 ug ofMBP-NS3-NS4A (at a final concentration of 0.0603~M) and 12~g of the synthetic peptide (at a final concentration of 26~). The reaction temperature was 37"C. After an adequate incubation period, the reaction was stopped by adding 4~L of 2.5 M acetic acid; the reaction mixture was then transferred to a vial for HPLC analysis.Analytical HPLC was carried out using a Tosoh SC-8020 liquid chromatography system, complete with a binary solvent delivery system, a heated column compartment and an auto-injection system. The HPLC conditions were as follows: ODS-80Ts column, 0.46x15 ern (Tosch); buffer D, 0.1% trifluoroacetic acid (TFA) in water; buffer E, 0.09% TFA in 90% acetonitrile; 0-50% buffer D gradient over a 20 min period at a flow rate of 1.0 mL min", Peptides were detected by UV absorbance at 214 nm. The cleavage products, product A (Dansyl-GEAGDDIVPC) and product B (SMSYTWT-GAL-OH), were quantified from their peak heights.
The inhibition of NS3-NS4A protease activity was tested with an HPLC assay system. The MBP-NS3-NS4A was pretreated with inhibitors (at a final concentration of 100~g mL-l) for 15 min at 37"C. Then, the proteolytic reactions were initiated by the addition of the synthetic substrate described above and incubated for 1 h at 37"C. The percentage of NS3-NS4A inhibition was calculated from the peak height of product A.
The inhibitory effects against other human serine protease were evaluated using a fluorogenic assay system. Fluorogenic peptides were used as specific substrates for the quantitative measurement of serine proteases, as described previously (Sawada et al., 1983; Oshima et al., 1984) . The following fluorogenic peptides were purchased Table 2 . Inhibitory activity of THNB derivatives against other serine proteases an incubation period of 3 h rather than 1 h; these differences may have affected the results. We ascertained the effects of an NS4A fragment (4A18-40), derived from residues 18-40 of NS4A, on NS3-NS4A protease activity in the presence of a 50-fold molar excess of 4A18-40. The rate of substrate cleavage by NS3-NS4A protease was accelerated in the presence of 4A18-40 (data not shown). It suggests that incomplete molecules as protease remain in the NS3-NS4A complex expressed in E. co/i. When R is an N-alkyl chain, THNB derivatives with a long chain, such as RD3-4082, show the strongest inhibition. However, two derivatives with short chains of three carbons or four carbons showed less than 50% inhibition at 100 J.lg mL-1 (data not shown). On the other hand, several derivatives with phenyl group had a higher inhibitory effect. Derivatives with p-phenoxy phenyl (RD3-4078), 2,3-dichlorophenyl (RD3-4077) and r:
bromophenyl (RD3-4079) groups showed a strong inhibitory effect. Moreover, three toryl benzarnides inhibited the NS3-NS4A protease with IC so value ofless than 50 J.lg mL-1; the derivative with a p-toryl group (RD2-4037) strongly suppressed it. These results indicate that the 2,4,6-trihydroxy,3-nitro-benzamide structure is an important factor that affects the anti-NS3-NS4A protease activity of the compound.
The mode of RD3-4077 inhibition of NS3-NS4A protease activity was examined biochemically. The Michaelis constant, K m , was calculated to be 65.7 J.lM, consistent with that determined previously . Moreover, inhibition constants K; (inhibition of free enzyme) and K;i (inhibition of enzyme-substrate complex) were determined to be 11.4 and 6.9 J.lM, respectively. This kinetic analysis revealed that the mode of action of RD3-4077 on HCY protease was a mixture of non-competitive and uncompetitive inhibition.
from Peptide Institute (Osaka, Japan): 3114-v [Sue-AlaAla-Pro-Phe-MCA(4-methylcoumaryl-7-amide)], specific for chymotrypsin; and 3100-v (Sue-Ala-Pro-Ala-MCA), specific for elastase. Chymotrypsin was purchased from Funakoshi (Tokyo, Japan). Elastase was purchased from Sigma. Elastinal was purchased from Peptide Institute. Chymostatin was purchased from Genosys BioTechnologies (Cambridge, UK).
The fluorogenic assaywas performed in PBS using 96-well microtitre trays (MS-8596, Sumitomo Bakelite, Tokyo, Japan). Serial fivefold dilutions of the inhibitors were made directly in the microtitre trays using an eight channel pipette. In a final volume of 200 J.lL, peptidyl-MCA substrates (at a final concentration of 0.1 mM) were mixed with chymotrypsin (0.001 mg mL-l) or elastase (1 mg mL-l). The plates were incubated for 1 h at 3TC.
Enzymatic activity was measured by fluorophotometric determination (excitation wavelength, 380 nm; emission wavelength, 460 nm) using Fluostar (Tecan Japan, Tokyo, Japan).
The inhibition of NS3-NS4A protease activity by THNB derivatives was measured and inhibitory concentration (IC so ) values were calculated; the results are summarized in Table 1 . Twelve derivatives assayed produced more than 50% inhibition at 100 J.lg mL-l. The following derivatives, listed with their IC so values, were most significant: RD3-4082, 2.3 J.lg mL-l (5.8 J.lM); RD3-4078, 8.5 J.lg mL-l (22.2 J.lM); RD3-4077, 10.8 J.lg mL-1 (28.1 J.lM). Recently, the efficacy of several potent protease inhibitors against HCY protease activity were evaluated using the HPLC method and a trans-cleavage assay using in vitro transcription and translation (D'Souza et al., 1995; Hahm et al., 1995; Lin & Rice, 1995; . Three serine protease inhibitors showed at least 50% inhibition ofNS3-NS4A protease activity at concentrations higher than those of the THNB derivatives.These serine protease inhibitors, listed with their IC so values, were: N-tosyl-L-Iysyl chloromethyl ketone (TLCK), 55.4 J.lg mL-1; chymostatin, 344.8 J.lg mL-1; and diisopropyl fluorophosphate, 415.9 ug mL-l .
Other reports suggest that serine protease inhibitors do not consistently inhibit the HCY protease (D'Souza et al., 1995; Lin & Rice, 1995) ; yet 12 THNB derivatives inhibited HCY protease activity at lower concentrations. When we evaluated the NS3 inhibitory effects of the three THNB derivatives that had been found to inhibit markedly the NS3-NS4A ,HCY protease activity, we found IC so values obtained in the NS3 inhibition assay were: RD3-4082, 1.2 J.lg mL-1; RD3-4078, 3.1 J.lg mL-l; RD3-4077, 4.8 J.lg mL-l. These results suggest that THNB derivatives inhibit the protease activity of NS3 without affecting NS4A. However, the NS3 inhibition assay was performed with fivefold more protease in comparison to the NS3-NS4A inhibition assay and with Table 2 shows the inhibitory effect ofTHNB derivatives against other serine proteases. The derivatives that strongly inhibited HCV protease also had inhibitory effects on other serine proteases. Almost all of the THNB derivatives showed 50% inhibition of at least one serine protease at lower concentrations than those of derivatives inhibiting the NS3-NS4A protease. A protease assay was performed based on the following IC so values: chymostatin, which specificallyinhibits chymotrypsin, 0.0049 Ilg mL-l; and elastinal, which specifically inhibits elastase, 1.35 Ilg mL-l. The thiazolidine derivative RD3-4082, which most strongly inhibited HCV protease, inhibited chymotrypsin at lower concentrations than that at which it inhibited the HCV protease NS3-NS4A. Similarly, the derivatives RD3-40n and RD3-4078 inhibited chymotrypsin at a lower concentration than that at which they inhibited HCV protease. However, derivative RD2-4039 inhibited the HCV protease at lower concentrations than those at which it inhibited the two other serine proteases. The selectivity index of RD2-4039 was especially significant: 3.0 against chymotrypsin, and >3.0 against elastase.
Most of the THNB derivatives tested displayed a broad range of effects, inhibiting NS3-NS4A protease activity along with the activities of chymotrypsin and elastase. This lack of specificity, and degree of inhibition against human serine protease make THNB derivatives themselves inappropriate candidates for clinical use. However, the selective inhibition ofHCV protease activity by RD2-4039 suggests a protease inactivator design that incorporates structural features of THNB may be effective. Moreover, these compounds may be of greater use as tools to understand the mechanism of action of the HCV protease.
